Tips on Surviving an FDA Inspection
Jo
Sanders, Christchurch
Clinical Studies Trust (CCST)
The FDA
regularly conducts inspections of
clinical trial facilities both domestically and internationally to determine a
site’s compliance with regulations and protocol adherence. Upon completing the inspection the FDA inspector
provides an initial verbal classification of the inspection. This is based on the observations noted
during the inspection, the investigator’s report, and FDA District Office
supervisory personnel review.
If the
inspector finds any objectionable conditions the clinical trials unit is
presented with an FDA Form 483, which includes the name of the site, dates of
inspection, and lists the observations made by the investigator during the
inspection.
In May 2017
Christchurch Clinical Studies Trust was inspected by the FDA.
This presentation will provide some of the background into the
inspection and will cover the following topics in relation to the inspection:
- · Preparation
required by the clinical trial site prior to the Inspector arriving
- · Expectations
of the FDA prior to the visit and once on site
- · The Sponsor’s
involvement
- · The
CRO role in the inspection
- · Resource
allocation required
- · Tips
on surviving the inspection